Consistent with preclinical and clinical studies, we found that targeting PD‐L1 alone was not effective in reducing tumor burden, whereas CD47 treatment sensitized the tumor to the immune system and significantly reduced tumor growth. This evidence concerns the gene CD274 and neoplasm.